On September 1, 2015, subject five was enrolled in our ongoing study of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness. Led by Principal Investigator Phil Wolfson, M.D., with co-therapist Julane Andries, LMFT, in Marin, Calif., this study will treat 18 subjects suffering from anxiety related to a life-threatening disease that is either ongoing or in remission with a possibility of recurrence. "We’re very excited to see the results from the first group of participants in this study,” says Ben Shechet, Clinical Research Associate for MAPS Public Benefit Corporation. "The reports from the study therapists regarding these subjects’ experimental sessions have been extremely positive, and we look forward to seeing how those experiences will be reflected in the data now coming in."
